Terminal complement activation is increased and associated with disease severity in CIDP

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

(2015) Isaak Quast et al.   JOURNAL OF CLINICAL INVESTIGATION

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype

(2015) Emily K Mathey et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

An open label clinical trial of complement inhibition in multifocal motor neuropathy

(2011) Amanda M. Fitzpatrick et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Advances in the diagnosis, pathogenesis and treatment of CIDP

(2011) Marinos C. Dalakas   Nature Reviews Neurology

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision

(2010)   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Complement activation and inhibition: a delicate balance

(2009) A.P. Sjöberg et al.   TRENDS IN IMMUNOLOGY

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model

(2008) Susan K. Halstead et al.   BRAIN

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

(2008) Richard AC Hughes et al.   LANCET NEUROLOGY